Study: Amgen drug may bring new approach to treat ITP

12/10/2007 | Bloomberg

Amgen's experimental treatment for idiopathic thrombocytopenic purpura not only reduced the risk of severe bleeding, but also helped preserve a healthy number of platelets in patients with the immune disorder, scientists revealed. The biotech firm is seeking FDA approval to market the drug, labeled AMG-531, while it ramps up development to launch the product as the first to stimulate platelets to treat ITP.

View Full Article in:

Bloomberg

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Clinical Trials Agreements Specialist (209955)
The Henry M. Jackson Foundation for the Advancement of Military Medicine Inc.
Rockville, MD
SAFETY, HEALTH, and ENVIRONMENTAL (SHE) REGIONAL SPECIALIST
Matheson Tri-Gas, Inc.
Newark, CA
Catheter Engineer
ASAHI INTECC, Orange County CA R&D Center
Santa Ana, CA
MANAGER MEDICAL GAS COMPLIANCE AND SAFETY
Matheson Tri-Gas, Inc.
Houston, TX
Neurovascular Intervention Product Sales Rep, North East
ASAHI INTECC
Multiple Locations, SL_Multiple Locations